EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 100 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $109 | -45.8% | 355,867 | +24.6% | 0.01% | -55.0% |
| Q2 2023 | $201 | +14.9% | 285,677 | +46.1% | 0.02% | +17.6% |
| Q1 2023 | $175 | +90.2% | 195,504 | +150.5% | 0.02% | +54.5% |
| Q4 2022 | $92 | -100.0% | 78,031 | -57.8% | 0.01% | -90.9% |
| Q4 2021 | $960,000 | -3.0% | 184,980 | +24.8% | 0.12% | +19.8% |
| Q3 2021 | $990,000 | +45.4% | 148,185 | +85.4% | 0.10% | +31.2% |
| Q2 2021 | $681,000 | +189.8% | 79,912 | +200.7% | 0.08% | +97.4% |
| Q1 2021 | $235,000 | -85.9% | 26,575 | -80.4% | 0.04% | -85.7% |
| Q4 2020 | $1,666,000 | +59.3% | 135,536 | +5.5% | 0.27% | +56.9% |
| Q3 2020 | $1,046,000 | +377.6% | 128,491 | +463.5% | 0.17% | +42.6% |
| Q2 2020 | $219,000 | +14.1% | 22,802 | +76.6% | 0.12% | +454.5% |
| Q4 2019 | $192,000 | -3.5% | 12,915 | -33.5% | 0.02% | -18.5% |
| Q3 2019 | $199,000 | -59.1% | 19,434 | -57.7% | 0.03% | -50.9% |
| Q2 2019 | $487,000 | – | 45,919 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Telemetry Investments, L.L.C. | 135,848 | $2,024,000 | 6.74% |
| INTERWEST VENTURE MANAGEMENT CO | 764,918 | $11,397,000 | 4.91% |
| Knoll Capital Management, LLC | 350,238 | $5,219,000 | 3.85% |
| 683 Capital Management, LLC | 1,850,000 | $27,565,000 | 3.15% |
| Soleus Capital Management, L.P. | 205,407 | $3,060,000 | 2.95% |
| Broadfin Capital, LLC | 1,236,368 | $18,422,000 | 2.47% |
| P.A.W. CAPITAL CORP | 144,000 | $2,146,000 | 2.29% |
| MANGROVE PARTNERS IM, LLC | 847,284 | $12,625,000 | 1.85% |
| Corriente Advisors, LLC | 203,898 | $3,038,000 | 1.63% |
| Trellus Management Company, LLC | 63,850 | $951,000 | 1.59% |